NCT06399302 Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
| NCT ID | NCT06399302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Lung Transplant; Complications |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,600 participants |
| Start Date | 2024-09-03 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,600 participants in total. It began in 2024-09-03 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at Lung Transplant Centers. The goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. The project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.
Eligibility Criteria
Inclusion Criteria: 1. Able to understand and provide informed consent 2. ≥ 18 years of age at the time of written informed consent 3. Anticipated listing or listed for a single or bilateral cadaveric donor lung transplant or having received a lung transplant within 30 days * Participants undergoing repeat lung transplantation or multi-organ transplantation are eligible if they meet the inclusion/exclusion criteria. Exclusion Criteria: 1. Unwillingness of a participant or legally authorized representative (LAR) to give written informed consent or comply with study protocol 2. Pregnancy or plans to become pregnant 3. Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Contact & Investigator
Scott M Palmer, MD, MHS
PRINCIPAL INVESTIGATOR
Duke University School of Medicine, Department of Medicine
Frequently Asked Questions
Who can join the NCT06399302 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Transplant; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06399302 currently recruiting?
Yes, NCT06399302 is actively recruiting participants. Contact the research team at allyn.damman@duke.edu for enrollment information.
Where is the NCT06399302 trial being conducted?
This trial is being conducted at Los Angeles, United States, San Francisco, United States, Stanford, United States, Miami, United States and 11 additional locations.
Who is sponsoring the NCT06399302 clinical trial?
NCT06399302 is sponsored by Duke University. The principal investigator is Scott M Palmer, MD, MHS at Duke University School of Medicine, Department of Medicine. The trial plans to enroll 2,600 participants.